3SBio Signs a License Agreement with Samsung Bioepis for its Biosimilars

Shots:

• Samsung to receive upfront, milestone and royalties on sales. 3SBio to get development & commercialization rights for Samsung’s biosimilars including SB8 (bevacizumab, Avastin) in China
• The focus of the agreement is for the expansion of Samsung’ biosimilar portfolio in China with its commercialization in the US, EU and Canada
• SB8 (bevacizumab, Avastin) is a mAb evaluated in P-III, indicated for the treatment of metastatic or recurrent non-squamous NSCLC

Click here to read full press release/ article | Ref: Samsung Bioepis | Image: Twitter